Elisa Agostinetto· @ElisaAgostinett · X·· 1 day agoScore70
Body · original
At #ESMO26 Proffered Paper 2️⃣ on #breastcancer
Results of the FINER trial
Ipatasertib + fulvestrant does not improve OS, neither overall nor in the AKT-mut cohort
Improvement in PFS and longer time to subsequent systemic tx or death
@OncoAlert
41 views · 3 likes · 3 reposts · 0 replies
Conference abstracts
LBA14matched by Proffered paper 2: Breast cancer, early and advanced stage
A double-blind placebo controlled randomized phase III trial of fulvestrant and ipatasertib as treatment for HER-2 negative and estrogen receptor positive (ER+) metastatic breast cancer (MBC): Overall survival results of the CCTG/BCT MA.40/
https://esmocongress.esmo.orgSource: Elisa Agostinetto · x.com